Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub 2009 Feb 13.
The 70-gene signature (MammaPrint) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II-III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.
70 基因标志物（MammaPrint）是一种预后工具，用于指导辅助治疗决策。本研究旨在评估其在新辅助治疗环境下预测化疗敏感性的价值。我们在新辅助化疗前获得了 II-III 期患者的 70 基因谱，并对预后标志物进行了分类。病理完全缓解（pCR）用于衡量化疗敏感性。在 167 例患者中，144 例（86%）患者预后不佳，23 例（14%）患者预后良好。预后良好的标志物患者无一例达到 pCR（0/23），而预后不佳的标志物患者中则有 29 例（20%）达到了 pCR（P = 0.015）。所有三阴性肿瘤（n = 38）均有预后不佳的标志物。在非三阴性亚组中，原发性肿瘤的反应仍然与预后标志物的分类相关（P = 0.023）。具有良好预后标志物的肿瘤不太可能达到 pCR。预后不佳的标志物肿瘤对化疗更敏感。
